Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Cheplapharm Arzneimittel

Request full access

A Sustainable Platform for Specialty Pharma

Greifswald, GermanyFounded 1998Biotech & Life Sciences

About Cheplapharm Arzneimittel

Cheplapharm Arzneimittel operates as a specialty pharmaceutical company with a distinct "buy-and-build" strategy, positioning itself as a key divestment partner for large pharmaceutical corporations. Founded in 1998 by Kurt Teubner, a former manager at Ciba Geigy (now Novartis), the company was acquired by the Braun family in 2003. Following the acquisition, Sebastian F. Braun, son of the new owners, was appointed CEO and relocated the firm's operations. The company's name is derived from Cheplaren, a plant-based diuretic and one of the first products it acquired.

The core of Cheplapharm's business model is the acquisition of mature, off-patent, and niche branded pharmaceutical products from major industry players like Merck, Roche, AstraZeneca, and Sanofi. This asset-light approach focuses on acquiring intellectual property rights and then outsourcing manufacturing, distribution, and marketing activities, which eliminates in-house research and development costs. Revenue is generated through the global sales of this diversified product portfolio, which includes over 125 branded products and more than 3,200 marketing authorizations across 145 countries. This strategy has resulted in consistent double-digit annual growth and a high degree of geographical and product diversification.

Cheplapharm's portfolio is extensive, covering a wide range of therapeutic areas including cardiology, oncology, gastroenterology, and emergency medicine. Key acquired products include well-known brands such as Xenical (anti-obesity), Dilatrend (beta-blocker), Vesanoid (leukemia medication), and Rohypnol (sleep medicine). The company manages the entire lifecycle of these established drugs, ensuring their continued availability for patients worldwide and serving a global market without being overly reliant on any single country for its sales. The firm actively seeks out and integrates products that larger companies intend to divest for strategic reasons, thereby extending the commercial life of these medicines. This has proven to be a robust model, with acquisitions being a primary driver of the company's significant revenue and EBITDA growth.

Source: Dealroom company data

At a glance

Status
Listed
Employees
510
Open positions
15
Dealroom signal
53.9/100
Industry
Health
Sub-industry
Pharmaceutical
Sector
Biotechnology, Outside Tech
Business model
SaaS
Client focus
B2B

Funding history

6 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
POST IPO EQUITY✓Other financing Sep 2026 — — Sanofi ↗
POST IPO DEBT✓Debt Feb 2026 $1B — Undisclosed ↗
Showing the latest 2 of 6 recorded eventsBook a demo for the full funding history →

Growth signals

Cheplapharm Arzneimittel website traffic

Latest recorded traffic for Cheplapharm Arzneimittel is 10K monthly website visits, up 23.5% over the last three months. Cheplapharm Arzneimittel's team grew 9.2% over the past year.

Latest monthly visits10K 3-month web change+23.5% 1-year team growth+9.2%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Cheplapharm Arzneimittel in the Greifswald ecosystem

Live from Dealroom

The Cheplapharm Arzneimittel office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

3 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A2 investors entered at this stage

Series B and later1 investor entered at this stage

  • Sanofi
Team profiled 6 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 5 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇩🇪 Germany · Greifswald HQ
Book a demo for the full country breakdown

See Cheplapharm Arzneimittel’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.